Abbott Laboratories
ABT· NYSE
ABTAbbott Laboratories
Filed Feb 17, 2023 · 10-K · 48 days after period end · 0001628280-23-004026
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 |
|---|---|---|---|---|
| Revenue | $10.09B | $11.47B | $10.70B | $8.31B |
| Net Income | $1.03B | $1.99B | $2.16B | $1.05B |
| EPS Diluted | — | — |
Abbott Laboratories · CIK 1800 · Engraved from SEC EDGAR
| — |
| $0.59 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2022 · filed Feb 17, 2023 · 48 d after period end
